Categories: News

Medanta Expands Indore Presence with Takeover of 80 Bed Cancer Hospital

GURUGRAM, India, April 27, 2026 /PRNewswire/ — Global Health Limited ‘Medanta’, one of the largest private multi-specialty tertiary care providers operating in the North and East regions of India, today announces the plan to takeover 80 bedded Cancer Hospital in Indore, Madhya Pradesh under a Business Transfer Agreement (BTA). This takeover strengthens Medanta’s presence in Central India and complements its existing 175-bedded multi-specialty hospital.

- Advertisement -

Strategically located just 500 meters from the current Medanta Indore facility, the newly-built Cancer Care Hospital will enable the launch of a comprehensive oncology program, enhancing Medanta’s specialty offerings in Indore. The integration is expected to drive operational synergies, optimise capacity utilisation, and improve patient flow across both facilities.

- Advertisement -

Under the Business Transfer Agreement, Asian Institute of Oncology Private Limited as the transferor, will transfer the Indore Business Undertaking (AIOPL Indore) as a going concern to Medanta, the transferee. Medanta will pay a consideration of Rs. 30 crores for the transfer of business, including the assignment of the long-term lease.

- Advertisement -

Commenting on the transaction, Mr. Pankaj Sahni, Group CEO, Medanta, said: “The takeover of the 80 bedded Cancer hospital in Indore is an extension of Medanta’s existing hospital in the city. With state-of-the-art oncology infrastructure, this facility enables us to add comprehensive cancer care, a previously missing specialty while further expanding our existing range of services. The hospital complements our Indore campus, enhancing patient access and creating operational synergies across the two facilities. This integration reinforces Medanta’s commitment to delivering advanced, patient-centric healthcare and strengthening our position as a leading provider of specialized high quality care in the region.”

- Advertisement -

About Global Health Limited (Medanta):

- Advertisement -

Founded by Dr. Naresh Trehan, a world-renowned cardiovascular and cardiothoracic surgeon who has been awarded the prestigious Padma Bhushan and the Padma Shri, the third- and fourth-highest civilian awards in India, and the Dr. B.C. Roy Award in recognition of his distinguished contribution to medicine.

- Advertisement -

Global Health Limited (the “Company”) is one of the largest private multi-specialty tertiary care providers operating in the North and East regions of India, with key specialties cardiac science, neurosciences, oncology, digestive and hepatobiliary sciences, orthopedics, liver transplant, and kidney and urology, according to the report titled ‘An assessment of the healthcare delivery market in India, September 2022’ by CRISIL Limited.

- Advertisement -

Under the ‘Medanta’ brand, the Company has a network of six hospitals currently in operation (Gurgaon, Indore, Ranchi, Lucknow, Patna and Noida). Spanning an area of 5.6 million sq. ft., its operational hospitals have 3,579 installed beds as on December 31, 2025. It also has five upcoming hospitals in Mumbai, Guwahati, Varanasi and two hospitals in Delhi. The Company provides healthcare services in over 30 medical specialties and engages over 2,300+ doctors led by highly experienced department heads.

- Advertisement -

Logo: https://mma.prnewswire.com/media/2966457/Medanta_Logo.jpg

- Advertisement -

 

- Advertisement -

View original content to download multimedia:https://www.prnewswire.com/in/news-releases/medanta-expands-indore-presence-with-takeover-of-80-bed-cancer-hospital-302754310.html

- Advertisement -

Recent Posts

Deepak Group Goes Beyond Green with hands-On Mangrove Restoration

Deepak Group undertakes mangrove plantation drive on World Environment DaySustainable restoration along the Paniyadra coast,…

8 hours ago

Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (ADA) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study

•Translational data presented at ADA demonstrate icovamenib’s potential to promote muscle preservation and fat reduction,…

12 hours ago

Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026

Presentations will feature clinical results for ribupatide, a GLP-1/GIP receptor dual agonist being developed as…

12 hours ago

Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress

Clinical benefit, including remissions, demonstrated in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA)…

12 hours ago

Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules

June 05, 2026 20:13 ET  | Source: Bluejay Diagnostics, Inc. $8.5 million upfront with up…

12 hours ago